Follistatin-344

Follistatin-344 is the 344-amino acid isoform of follistatin, a naturally occurring glycoprotein that potently inhibits myostatin and activin A — two TGF-β superfamily members that limit muscle growth. By blocking these inhibitory signals, Follistatin-344 creates conditions for dramatic increases in lean muscle mass. It has been studied via AAV-mediated gene therapy in clinical settings and as a recombinant peptide in preclinical research. Human data is extremely limited and no injectable follistatin protocol has been validated in clinical trials.

Follistatin-344 is a secreted glycoprotein that acts as a high-affinity binding protein and functional antagonist of myostatin (GDF-8) and activin A, both of which are members of the TGF-β superfamily. By binding these ligands extracellularly, follistatin prevents them from engaging their type I/II serine-threonine kinase receptors (ActRIIA/B, ALK4/5), thereby blocking the downstream SMAD2/3 signaling cascade that restricts muscle fiber hypertrophy and promotes atrophy. The resulting disinhibition of mTOR and satellite cell activation drives both hypertrophy of existing fibers and hyperplasia via myoblast proliferation. The 27-amino acid C-terminal extension unique to FS-344 enhances heparan sulfate proteoglycan binding on cell surfaces, prolonging local tissue retention versus the shorter FS-315 isoform. Follistatin also suppresses activin-driven FSH secretion from the pituitary, with significant reproductive endocrine consequences.

Most human evidence comes from a gene therapy trial using AAV1-FS344 in Becker muscular dystrophy and inclusion body myositis patients, which demonstrated increased muscle volume and strength over 2 years without serious adverse events. Preclinical data in mice, primates, and dogs consistently shows marked increases in muscle mass (2-3x) with myostatin inhibition. No injectable recombinant follistatin-344 peptide human trials exist — all community protocols are extrapolated from animal data or gene therapy studies. A 2020 case series documented 11 male bodybuilders who developed central serous chorioretinopathy (CSCR, a retinal condition) following subcutaneous follistatin-344 injections, suggesting real ocular risk. FSH suppression (up to 75% reduction within one week in animal models) raises fertility concerns.

Peptides commonly paired with Follistatin-344 for synergistic effects.